Published in J Natl Cancer Inst on February 21, 2013
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med (2014) 1.51
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology (2014) 0.90
Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med Genomics (2015) 0.90
Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv Drug Deliv Rev (2013) 0.89
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget (2016) 0.85
Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia. Oncotarget (2015) 0.83
Preclinical models of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.83
From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol (2015) 0.82
Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems. Front Oncol (2014) 0.81
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget (2015) 0.81
The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. J Natl Cancer Inst (2015) 0.81
Precision medicine for cancer patients: lessons learned and the path forward. J Natl Cancer Inst (2013) 0.80
A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol (2015) 0.80
Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer (2015) 0.79
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues. Oncotarget (2015) 0.79
Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. BMC Pharmacol Toxicol (2014) 0.79
Identification of reproducible drug-resistance-related dysregulated genes in small-scale cancer cell line experiments. Sci Rep (2015) 0.79
Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer (2016) 0.78
Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. Biomaterials (2013) 0.78
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins. PLoS One (2014) 0.78
Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche. PLoS One (2015) 0.78
Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nat Rev Clin Oncol (2016) 0.78
Assessing Antioxidant Capacity in Brain Tissue: Methodologies and Limitations in Neuroprotective Strategies. Antioxidants (Basel) (2014) 0.77
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations. Transl Oncol (2016) 0.77
Drosophila as a Potential Model for Ocular Tumors. Ocul Oncol Pathol (2015) 0.77
Near infrared optical visualization of epidermal growth factor receptors levels in COLO205 colorectal cell line, orthotopic tumor in mice and human biopsies. Int J Mol Sci (2013) 0.77
Drug sensitivity in cancer cell lines is not tissue-specific. Mol Cancer (2015) 0.77
Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. BMC Cancer (2016) 0.77
Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy. Oncogenesis (2016) 0.76
Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res (2015) 0.76
Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. PLoS One (2016) 0.76
Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia. Leukemia (2016) 0.76
Ex vivo construction of human primary 3D-networked osteocytes. Bone (2017) 0.76
Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia. J Investig Med (2016) 0.75
Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance. Expert Rev Anticancer Ther (2015) 0.75
Drug Delivery Approaches for the Treatment of Cervical Cancer. Pharmaceutics (2016) 0.75
Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget (2016) 0.75
Efficient and simple approach to in vitro culture of primary epithelial cancer cells. Biosci Rep (2016) 0.75
An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells. Front Bioeng Biotechnol (2017) 0.75
The ability of hyaluronan fragments to reverse the resistance of C6 rat glioma cell line to temozolomide and carmustine. Contemp Oncol (Pozn) (2014) 0.75
Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. J Transl Med (2016) 0.75
Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer (2016) 0.75
p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer. Oncogene (2016) 0.75
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation. Oncotarget (2016) 0.75
Multi-cycle chemotherapy with the glycolipid-like polymeric micelles evade cancer stem cell enrichment in breast cancer therapy. Oncotarget (2016) 0.75
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget (2016) 0.75
Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet (2017) 0.75
Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474. Oncotarget (2017) 0.75
A high-content image analysis approach for quantitative measurements of chemosensitivity in patient-derived tumor microtissues. Sci Rep (2017) 0.75
Ex vivo replication of phenotypic functions of osteocytes through biomimetic 3D bone tissue construction. Bone (2017) 0.75
BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma. PLoS One (2017) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med (1953) 25.88
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
A global map of human gene expression. Nat Biotechnol (2010) 5.32
The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer (2007) 4.40
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet (1985) 3.23
Cell line misidentification: the beginning of the end. Nat Rev Cancer (2010) 2.87
Banded marker chromosomes as indicators of intraspecies cellular contamination. Science (1974) 2.84
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci (2011) 2.09
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Next-generation sequencing: ready for the clinics? Clin Genet (2012) 1.75
Drug discovery: Cell lines battle cancer. Nature (2012) 1.70
Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer (2008) 1.65
From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst (2008) 1.60
Source, alterations, characteristics and use of a new dog cell line (Cf2Th). In Vitro (1976) 1.49
Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res (1999) 1.37
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol (2003) 1.36
Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. In Vitro Cell Dev Biol Anim (2010) 1.35
Maintaining differentiated cellular identity. Nat Rev Genet (2012) 1.32
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data. BMC Genomics (2006) 1.24
Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle (2010) 1.18
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol (2008) 1.11
Inter- and intraspecies contamination of human breast tumor cell lines HBC and BrCa5 and other cell cultures. Science (1977) 1.07
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
Short tandem repeat profiling: part of an overall strategy for reducing the frequency of cell misidentification. In Vitro Cell Dev Biol Anim (2010) 1.05
Evidence for multidrug-resistant cells in human tumor cell populations. Cancer Treat Rep (1983) 1.05
How accurate are cancer cell lines? Nature (2010) 1.05
Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin Chem (2006) 1.02
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol (2011) 0.94
Human tumor xenografts as model for drug testing. Cancer Metastasis Rev (1988) 0.93
Drug resistance in the mouse cancer clinic. Drug Resist Updat (2012) 0.89
Artefactual effects of oxygen on cell culture models of cellular senescence and stem cell biology. J Cell Physiol (2011) 0.89
Use of the KB cell line for in vitro cytotoxicity assays. Cancer Treat Rep (1983) 0.87
KB cell culture I. Role in discovery of antitumor agents from higher plants. J Nat Prod (1982) 0.80
The identification and monitoring of cell line specificity. Prog Clin Biol Res (1978) 0.77
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol (2005) 2.07
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
Calculating confidence intervals for prediction error in microarray classification using resampling. Stat Appl Genet Mol Biol (2008) 1.70
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res (2007) 1.53
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer (2014) 1.39
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 1.37
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry (2007) 1.33
Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res (2006) 1.31
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res (2008) 1.30
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther (2008) 1.28
High recombination rates and hotspots in a Plasmodium falciparum genetic cross. Genome Biol (2011) 1.27
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther (2004) 1.24
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther (2008) 1.22
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol (2004) 1.18
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A (2006) 1.18
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem (2009) 1.17
Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res (2006) 1.16
The sounds of silence: synonymous mutations affect function. Pharmacogenomics (2007) 1.14
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol (2002) 1.13
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res (2005) 1.12
The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat (2012) 1.12
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux. J Biol Chem (2002) 1.08
P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res (2003) 1.08
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res (2010) 1.05
Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res (2009) 1.05
Transcription poisoning by Topoisomerase I is controlled by gene length, splice sites, and miR-142-3p. Cancer Res (2013) 1.05
Structure of a multidrug transporter. Nat Biotechnol (2009) 1.04
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res (2013) 1.04
Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. J Cell Physiol (2005) 1.04
Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer. Nat Commun (2013) 1.03
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A (2011) 1.03
Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol (2004) 1.01
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Res (2012) 1.00
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics (2013) 1.00
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends Pharmacol Sci (2005) 0.98
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells (2012) 0.95
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics (2007) 0.93
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
Genome and transcriptome profiles of CD133-positive colorectal cancer cells. Am J Pathol (2011) 0.92
Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J Med Chem (2005) 0.91
High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum Gene Ther (2003) 0.91
In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gene Ther (2002) 0.90
Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol (2006) 0.90
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Drug Resist Updat (2012) 0.90
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet (2014) 0.89
A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem (2004) 0.89
Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J Med Chem (2011) 0.89
P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res (2007) 0.89
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro. Biotechniques (2004) 0.88
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem (2011) 0.88
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol (2010) 0.88
Construct and Compare Gene Coexpression Networks with DAPfinder and DAPview. BMC Bioinformatics (2011) 0.87
SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr Pharm Biotechnol (2004) 0.87
RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res (2011) 0.87
Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer. Cancer Res (2005) 0.86